retatrutide fat loss results Weight Results:Trial Data and FDA Status ✨ Big news in the

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double blind randomized controlled trials and nationwide disease and prescription registers

The two compounds operate through complementary but mechanistically distinct pathways

The doses used in compounded formulations are very low (2 mg per injection), which provides some reassurance

No new adverse reactions were identified in the DAPA-HF, DELIVER and DAPA-CKD trials

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial